Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term etoposide. Found 12 abstracts

Gokare P, Navaraj A, Zhang S, Motoyama N, Sung SS, Finnberg NK. Targeting of Chk2 as a countermeasure to dose-limiting toxicity triggered by topoisomerase-II (TOP2) poisons. Oncotarget. 2016 Apr 18;7(20):29520-30.   PMCID: PMC5045414
Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow L, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan TM, Koczywas M, Moran CA, Niell HB, O'Malley J, Patel JD, Ready N, Rudin CM, Williams CC. Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network. 2011 Oct;9(10):1086-113.   PMCID: not NIH funded
Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie T, Beck T, Ansar R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. 2006 May;24(13):2038-43.
Belinsky MG, Dawson PA, Shchaveleva I, Bain LJ, Wang R, Ling V, Chen ZS, Grinberg A, Westphal H, Klein-Szanto A, Lerro A, Kruh GD. Analysis of the in vivo functions of Mrp3. Molecular Pharmacology. 2005 Jan;68(1):160-8.
Komaki R, Swann RS, Ettinger DS, Glisson BS, Sandler AB, Movsas B, Suh J, Byhardt RW. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. International Journal of Radiation Oncology Biology Physics. 2005 Jun;62(2):342-50.
Machtay M, Hsu C, Komaki R, Sause WT, Swann RS, Langer CJ, Byhardt RW, Curran WJ. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: Analysis of the Radiation Therapy Oncology Group (RTOG) experience. International Journal of Radiation Oncology Biology Physics. 2005 Nov;63(3):667-71.
Tester WJ, Kim KM, Krigel RL, Bonomi PD, Glick JH, Asbury RF, Kirkwood JM, Blum RH, Schiller JH. A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer - An Eastern Cooperative Oncology Group study (PZ586). Lung Cancer. 1999 Sep;25(3):199-206.
Hudes GR, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B, Greenberg R, Gomella L, Litwin S, Ross E, Roethke S, McAleer C. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. Journal of Clinical Oncology. 1997 Sep;15(9):3156-63.
Ford PA, Arbuck SG, Minniti C, Miller LL, DeMaria D, Odwyer PJ. Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF. European Journal of Cancer. 1996 Apr;32A(4):631-5.
Comis RL. Extensive small cell lung cancer. Lung Cancer. 1993 Jan;9(SUPPL. 1).
Langer CJ, Curran Jr WJ, Keller SM, Catalano R, Fowler W, Blankstein K, Litwin S, Bagchi P, Nash S, Comis R. Report of phase II trial of concurrent chemoradiotherapy with radical thoracic irradiation (60 Gy), infusional fluorouracil, bolus cisplatin and etoposide for clinical Stage IIIB and bulky IIIA non-small cell lung cancer. International Journal of Radiation Oncology Biology Physics. 1993 Jan;26(3):469-78.
Comis RL. Oral etopside in oncology: An evolving role. Annals of Oncology. 1992 Jan;3(SUPPL. 3):63-7.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term etoposide

etoposide cisplatin doxorubicin carcinoma chemotherapy radiotherapy cyclophosphamide lung small cell cancer interferon trial colony-stimulating factor Combined modality therapy advanced cancer 1993 lisle l-archives of internal medicine-v153-p746 Concurrent chemoradiotherapy gamma- lung non small cell cancer metaanalysis combination chemotherapy Locally advanced non-small cell lung cancer hodgkins-lymphoma binding alpha interleukin 2 mutations neck-cancer surgical phase-iii modulation concurrent chemotherapy gefitinib survival vp-16-213 non-small-cell lung carcinoma cooperative-oncology-group breast-cancer daily thoracic radiotherapy Chk2 beta-interferon high-dose chemotherapy microtubule assembly invitro Radical thoracic radiation paclitaxel apoptosis killer-cells granulocyte recombinant interleukin-2 antineoplastic agent thoracic radiation therapy cancer proteins protein analysis thoracic radiotherapy resection cisplatin plus tubulin myelosuppression neuroendocrine tumors oral drug administration forthcoming 7th edition non- prophylactic cranial irradiation small vincristine phase-iii trial phase I trial treatment multicenter randomized-trial small-cell lung cancer fluorouracil non-small cell lung cancer NCCN Guidelines Extensive SCLC carboplatin multicenter trial interruptions favorable patients Oncology combined-modality treatment regimen GM-CSF gastric-cancer interleukin-2 vinblastine fractionation Stage III NSCLC topoisomerase inhibitors impact NCCN Clinical Practice Guidelines Dose intensity combination immunotherapy cis-dichlorodiammineplatinum(ii) head antigen multidrug resistance protein 3 positron-emission-tomography cell
Last updated on Wednesday, March 04, 2020